Antares Pharma Inc

Antares Pharma — Shareholder Meeting (May 2006)

42 slides from Antares Pharma's shareholder meeting presentation, May 5, 2006

  1. Slide 1: Antares Pharma Annual Meeting May 4, 2006

    Strictly Confidential ANTARES PHARMA, INC. ANNUAL MEETING MAY 4, 2006 Amex: AIS www.antarespharma.com www.mediject.com Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Antares Pharma, Inc. © 2006 Confidential This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that stateme

  3. Slide 3: Agenda

    Antares Pharma, Inc. © 2006 Confidential Overview Recent Accomplishments : Anturol™ Phase II results reported Estradiol Bio-E-Gel™ Other Financial Overview 2006 Value Drivers Agenda • • – – – • •

  4. Slide 4: Overview

    Strictly Confidential Overview

  5. Slide 5: Overview

    Antares Pharma, Inc. © 2006 Confidential Overview Organized by the Chairman, Jacques Gonella, Ph.D. (Jago Pharma) Three locations: Headquarters – Exton, PA Devices – Minneapolis, MN: Prototype modeling Pharma Development – Basel, Switzerland: GMP approved 27 employees 32 issued patents, 111 patents

  6. Slide 6: Alliances and Partnerships

    Alliances and Partnerships

  7. Slide 7: Corporate Partners

    Antares Pharma, Inc. © 2006 Confidential Corporate Partners

  8. Slide 8: Business Model

    Antares Pharma, Inc. © 2006 Confidential Business Model Validate technology with development partners Develop internal pipeline Out-license product rights in larger sectors Commercialize products in niche sectors of dermatology, pain, urology, CNS, and women’s health Acquire or license complimentary

  9. Slide 9: Pharmaceutical Technology Platforms

    Antares Pharma, Inc. © 2006 Confidential Pharmaceutical Technology Platforms EasyTec™ Orally Disintegrating Tablets Fast-Melt Tablet Technologies TecTix™ Transdermal/Topical Technology Eutectics Semisolid Technologies Topical Delivery Technology Local ATD ™ Combination Gels ATD ™ Single Gels Systemi

  10. Slide 10: ATD Advanced Transdermal Delivery Technology

    Antares Pharma, Inc. © 2006 Confidential ATD™ Advanced Transdermal Delivery Technology Antares Pharma Technologies: ATD™

  11. Slide 11: Antares Pharma Technologies: ATD - What is it?

    Antares Pharma, Inc. © 2006 Confidential Semi-solid formulations containing one or more drugs A hydro-alcoholic vehicle A combination of permeation enhancers Thickening agents A pH regulator Antares Pharma Technologies: ATD™ What is it? • • Increases drug partitioning into the skin Increases drug pa

  12. Slide 12: Advantages of ATD Gels

    Antares Pharma, Inc. © 2006 Confidential Antares Pharma Technologies: ATD™ Advantages of ATD™ Gels Reduces GI exposure Patented and able to deliver more than one drug • Avoids first - pass liver toxicity effects • • • Typically smaller doses • No irritation or occlusion • Leads to improved patient c

  13. Slide 13: TecTix Transdermal/Topical Technology

    Antares Pharma, Inc. © 2006 Confidential Antares Pharma Technologies: TecTix™ Eutectics Semisolid Technologies TecTix™ Transdermal/Topical Technology

  14. Slide 14: Antares Pharma Technologies: TecTix - What is it?

    Antares Pharma, Inc. © 2006 Confidential Melting point depression of API by Chemical Fragrance & Flavors Ingredients (CFFI) Versatile technology compatible with numerous API Alcohol-free liquid or semi-solid Patent-pending Technology (Priority date: August 23, 2005) What is it? Antares Pharma Techno

  15. Slide 15: Advantages of TecTix

    Antares Pharma, Inc. © 2006 Confidential CFFI with a long and safe history of use in toiletries, perfumes and cosmetics High thermodynamic activity Increase of lipophilic properties Higher dissolution rate faster onset-of-action Numerous API already successfully screened: NSAIDs Local anaesthetics N

  16. Slide 16: EasyTec Oral Disintegrating Tablet Technology

    Antares Pharma, Inc. © 2006 Confidential Fast Melt Tablet Technologies Antares Pharma Technologies: Easy Tec™ Easy Tec™ Oral Disintegrating Tablet Technology

  17. Slide 17: Antares Pharma Technologies: EasyTec - What is it?

    Antares Pharma, Inc. © 2006 Confidential - Hygroscopic disintegrant(s) - Water-soluble components - Large surface area (high porosity) Soft, friable, moisture-sensitive tablets The ideal ODT technology shall simultaneously achieve: 1) Rapid Oral Disintegration 2) Physical Stability AND EasyTec ODTs

  18. Slide 18: EasyTec Main Advantages

    Antares Pharma, Inc. © 2006 Confidential Simple and cost-effective Patented technology (US & EU) Superior palatability and mouth-feel Conventional packaging with low friability and moisture sensitivity Versatile for drug loadings Low cost of goods Antares Pharma Technologies: Easy Tec™ Main Advantag

  19. Slide 19: Anturol ATD Gel

    ANTUROL™ - ATD™ GEL

  20. Slide 20: Anturol Market Positioning

    Antares Pharma, Inc. © 2006 Confidential ATD ™ Oxybutynin Gel: Anturol ™ – Market Positioning Our innovative Overactive Bladder product will have… Fast onset of therapeutic activity Decreased incidence of systemic AE’s Lower incidence of local/on-site irritation Accurate, improved once-daily dosing

  21. Slide 21: Anturol Phase II clinical study summary

    Antares Pharma, Inc. © 2006 Confidential Anturol ATD™ Gel 48 subjects receiving three different treatments (low, intermediate, and high) over 20 consecutive days Anturol ATD™ Gel Phase II clinical study summary Dose proportionality and linear pharmacokinetics At intermediate dose, similar OXY averag

  22. Slide 22: Indirect comparisons Cavg DEO/OXY levels

    Antares Pharma, Inc. © 2006 Confidential Indirect comparisons Cavg DEO/OXY levels (Phase II) 3.0 4.3 5.4 3.0 4.0 7.0 4.2 10.1 4.5 60.4 12.7 5.8 0 10 20 30 40 50 60 70 80 OXY DEO Anturol™ Phase II Clinical Program DEO & OXY C avg (Surrogate for Efficacy) DITROPAN IR tablet 15mg/d DITROPAN XL tablet 1

  23. Slide 23: Phase II adverse events: skin erythema

    Antares Pharma, Inc. © 2006 Confidential Urology: Anturol™ ATD™ Gel Phase II adverse events: skin erythema Incidence of skin erythema: indirect comparison Anturol-Oxytrol 12 12 6 12 18 44 12 0 10 20 30 40 50 60 OXYTROL patch 36mg (delivers 3.9mg/d) ANTUROL gel low dose ANTUROL gel intermediate dose

  24. Slide 24: Anturol ATD Gel Accomplishments

    Antares Pharma, Inc. © 2006 Confidential Anturol ATD™ Gel Accomplishments Formulation development Completed First PK study in human Completed IND filing Completed Phase II study and report Completion in Jan 06 Tech-transfer Completion in Apr 06 End of Phase II meeting Completion in May 06 • • • • •

  25. Slide 25: Anturol Phase III and Timelines

    Antares Pharma, Inc. © 2006 Confidential Preliminary Phase III Currently under evaluation Urge and mixed urinary incontinence 12 week, Multi-center Two dose strengths, once daily, gel vs. placebo Scale-up to 500 kg batch size initiated with Patheon We have “freedom to operate” legal opinion Watson g

  26. Slide 26: Other ATD Transdermal Gels

    OTHER ATD™ TRANSDERMAL GELS

  27. Slide 27: Bio-E-Gel

    Antares Pharma, Inc. © 2006 Confidential Validated as first ATD™ product accepted by FDA Estrogen market $1.3 billion in U.S. and EU Market growing through 2010 Antares has milestones and royalties in U.S. Marketing rights in Europe and elsewhere Bio-E-Gel ™ NDA Accepted April 18, 2006 – – – – –

  28. Slide 28: LibiGel Testosterone for FSD

    Antares Pharma, Inc. © 2006 Confidential • ISSWSH Meeting in October 2005 reopened pathway • 240% increase in frequency of sexual activity. – No approved product in U.S. • 2006 Phase III Targeted by Partner – Phase II completed in 46 hysterectomized women, efficacious – Phase III clinical program de

  29. Slide 29: Other Recent ATD Developments

    Antares Pharma, Inc. © 2006 Confidential Development and license deals in CNS and Dermatology AP-1081 contraceptive ATD™gel: Ortho Evra® patch in preclinical AP-1022 Alprazolam ATD™gel: Xanax® for anti- anxiety disorders Other Recent ATD ™ Developments • • •

  30. Slide 30: Antares Pharma

    Me> antares pharma

  31. Slide 31: AP-159 EasyTec ODT Tablet Accomplishments

    Antares Pharma, Inc. © 2006 Confidential AP-159 Easy Tec™ Tablet Formulation development Completed 2005 In vitro dissolution test on final prototype Completed April 06 Manufacturing Tech-transfer Completed April 06 AP-159 Easy Tec™ ODT Tablet Accomplishments • • •

  32. Slide 32: Antares Pharma

    Me> antares pharma

  33. Slide 33: Valeo/Vision Reusable Needle-Free Injectors

    Antares Pharma, Inc. © 2006 Confidential • High-pressure for subcu delivery – Growing protein and macro - molecule markets (e.g. insulin, hGH, FSH, EPO, GCSF) • Insulin: Wal-Mart and Diabetic X • hGH field: Ferring and JCR • New Market in US • Insulin market: – Projected to grow from $7.7 billion in

  34. Slide 34: Disposable Mini-Needle Injectors for Antidote Delivery

    Antares Pharma, Inc. © 2006 Confidential Partner with government and private sector for bioterrorism Patented, pre-packed, portable, low cost, durable in adverse conditions BioShield: $5.6 billion for government procurement Does not require FDA approval Disposable Mini-Needle Injectors For Antidote

  35. Slide 35: TEVA Injector Deal

    Antares Pharma, Inc. © 2006 Confidential First commercial deal in device category Exclusive supplier Ramping up of product line currently Transfer price, royalties and milestones also TEVA Injector Deal November 28, 2005 • • • •

  36. Slide 36: Financial Overview

    Financial Overview

  37. Slide 37: Financial Overview

    Antares Pharma, Inc. © 2006 Confidential Financial Overview Market Cap $90 mm Shares Outstanding 53 mm Fully Diluted Shares 80 mm Diluted Shares in Money 73 mm Cash + Cash Equivalents $2.7 mm As of 12/31/05 Debt / Pfd Stock NONE As of 3/28/06 * * In the 1 st Qtr of 2006 AIS raised $10 mm Amex: AIS A

  38. Slide 38: Recent Accomplishments

    RECENT ACCOMPLISHMENTS

  39. Slide 39: Summary of Recent Accomplishments

    Antares Pharma, Inc. © 2006 Confidential Summary of Recent Accomplishments Positive Phase II results, Anturol™ NDA for Bio-E-Gel ™, estradiol ATD™ gel accepted by FDA First commercial injector deal with TEVA Added new CFO, Robert F. Apple Raised $11 million Announced TecTix™ DD system • • • • • •

  40. Slide 40: Antares Pharma

    Me> antares pharma

  41. Slide 41: 2006 Key Value Drivers

    Antares Pharma, Inc. © 2006 Confidential 2006 Key Value Drivers Initiate Phase III Clinicals for Anturol™ Next mini-needle (Vibex™) disposable injector deal Expand market for hGH opportunity First formulation of first TecTix™ product • • • •

  42. Slide 42: Strictly

    Strictly Confidential

Antares Pharma — Shareholder Meeting (May 2006) on 6ix